Avenir reports 8.3% Cytosorbents (CTSO) ownership stake in 13G/A

Rhea-AI Filing Summary

Avenir Corporation and James H. Rooney report significant ownership in Cytosorbents Corp. They disclose beneficial ownership of 5,230,099 shares of Cytosorbents common stock, representing about 8.3% of the outstanding class.

The filing states they share voting and dispositive power over these shares. Avenir is described as a Virginia-based investment adviser, and Rooney is its portfolio manager and shareholder. They certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Cytosorbents.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 05:56 PM Learn about SEC filing dates

FAQ

How much of Cytosorbents Corp (CTSO) do Avenir and James H. Rooney own?

Avenir Corporation and James H. Rooney report beneficial ownership of 5,230,099 Cytosorbents common shares, representing about 8.3% of the class. This stake gives them shared voting and shared dispositive power over those shares, according to the Schedule 13G/A amendment.

Who are the reporting persons in the Cytosorbents (CTSO) Schedule 13G/A filing?

The reporting persons are Avenir Corporation and James H. Rooney. Avenir is a Virginia corporation and registered investment adviser, while Rooney is Avenir’s portfolio manager and a shareholder, with both reporting shared voting and dispositive power over the same block of Cytosorbents shares.

What percentage of Cytosorbents (CTSO) common stock is reported as owned?

The Schedule 13G/A states that 5,230,099 Cytosorbents common shares are beneficially owned, representing approximately 8.3% of the outstanding class. This level of ownership requires public disclosure under beneficial ownership rules once it exceeds five percent.

Do Avenir and James H. Rooney intend to control Cytosorbents Corp (CTSO)?

They certify the securities were acquired and are held in the ordinary course of business, not to change or influence control of Cytosorbents. The filing also notes they are not participating in any transaction designed to affect control, other than limited nomination-related activities referenced in regulations.

What powers do Avenir and James H. Rooney have over their Cytosorbents (CTSO) shares?

The filing reports shared voting power and shared dispositive power over 5,230,099 Cytosorbents common shares. Shared voting power covers how the shares are voted, while shared dispositive power relates to decisions to sell or otherwise dispose of those shares.

Where are Avenir and Cytosorbents (CTSO) based according to the filing?

Cytosorbents’ principal executive offices are listed at 305 College Road East, Princeton, New Jersey 08540. Avenir’s principal business office is given as 277 South Washington Street, Suite 350, Alexandria, Virginia 22314, reflecting the locations tied to issuer and reporting person.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Cytosorbents Corp

(Name of Issuer)

Common Stock

(Title of Class of Securities)

23283X206

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23283X206

1

Names of Reporting Persons

AVENIR CORP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGINIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power
6	Shared Voting Power 5,230,099.00
7	Sole Dispositive Power
8	Shared Dispositive Power 5,230,099.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,230,099.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 23283X206

1

Names of Reporting Persons

James H. Rooney

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGINIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power
6	Shared Voting Power 5,230,099.00
7	Sole Dispositive Power
8	Shared Dispositive Power 5,230,099.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cytosorbents Corp
(b)	Address of issuer's principal executive offices: 305 COLLEGE ROAD EAST, PRINCETON, NEW JERSEY, 08540
Item 2.
(a)	Name of person filing: This Schedule 13G ("Schedule") is being filed on behalf of Avenir Corporation ("Avenir"), a Virginia corporation, and James H. Rooney (Mr. Rooney along with Avenir are "Reporting Persons"). Avenir is an investment adviser registered under the Investment Advisers Act of 1940, as amended ("Advisers Act"). Mr. Rooney is the portfolio manager and a shareholder of Avenir.
(b)	Address or principal business office or, if none, residence: 277 South Washington Street Suite 350 Alexandria, VA 22314
(c)	Citizenship: State of Virginia, USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 23283X206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,230,099
(b)	Percent of class: 8.33%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote:
	(ii) Shared power to vote or to direct the vote: 5,230,099
	(iii) Sole power to dispose or to direct the disposition of:
	(iv) Shared power to dispose or to direct the disposition of: 5,230,099
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AVENIR CORP

Signature:	James H. Rooney
Name/Title:	President
Date:	02/13/2026

James H. Rooney

Signature:	James H. Rooney
Name/Title:	President
Date:	02/13/2026